The extra general meeting ("EGM") of Frisq Holding AB (publ) ("FRISQ" or the "Company") was held on 8 February 2022 at 15:00 CET and the following resolutions were passed by the meeting.
Adjournment of the issue of sale of all shares in the subsidiaries until 22 February 2022
The EGM has decided to be adjourned and that a decision on the sale of all shares in the company's operating subsidiaries Frisq AB, Frisq UK LTD and Frisq USA Holding Inc shall be postponed until the continued general meeting, to be held at 15.00 CET on 22 February 2022 in Baker & McKenzie Advokatbyrås' premises at Vasagatan 7 in Stockholm.
Right to attend has each shareholder who was entered in the share register kept by Euroclear Sweden AB on the record date, which was Monday 31 January 2022, registered in the share register maintained by Euroclear Sweden AB, and who notifies the company of their participation and any assistants (no more than two) in the extra general meeting no later than Tuesday 1 February 2022. The notification shall be in writing to Frisq Holding AB (publ), Att: Thomas Edlund, Lästmakargatan 20, 111 44 or via e-mail: bolagsstamma@frisq.se. The notification should state the name, personal/corporate identity number, shareholding, share classes address and telephone number and, when applicable, information about representatives, counsels and assistants. When applicable, complete authorization documents, such as registration certificates and powers of attorney for representatives and assistants, should be appended the notification.
The notifications of participation to the extraordinary general meeting of today, also applies to participation in the continued extraordinary general meeting.
For further details regarding the resolution set out above refer to the complete proposals and notice available at the Company's website, www.frisqholding.se.
For further information:
George Thaw, CEO, FRISQ
investor@frisq.se
About FRISQ:
FRISQ is a healthtech company built on the conviction that the quality of the care you get should not be dependent on your ability to navigate a complex system and constantly evolving treatments. The software solution FRISQ Care enables the creation of personalized, digital care plans that facilitate collaboration and secure information sharing between care teams, doctors and patients through the same platform.
Since 2016, FRISQ has been listed on Nasdaq First North Stockholm under the symbol “FRISQ”. FNCA Sweden AB is FRISQ’s Certified Adviser and can be reached via the following contact information: +46 8 528 00 399, info@fnca.se
The publication is a translation of the original Swedish text. In the event of inconsistency or discrepancy between the Swedish version and this publication, the Swedish language version shall prevail.
For more information, please visit: www.frisqholding.se